Diagnostica Stago Acquires Dutch Thrombin Generation Company
By LabMedica International staff writers Posted on 20 Oct 2010 |
Diagnostica Stago, Inc. (DSI; Parsippany, NJ, USA), finalized the acquisition of Thrombinoscope, BV (Maastricht, The Netherlands). Originally developed at Maastricht University, Thrombinoscope, researches, develops, and markets thrombin generation (TG) systems through the use of the Calibrated Automated Thrombogram (CAT) system. The CAT system is available for research-only use.
"The development potential of this new TG approach in hemostasis using the CAT system is very promising," noted Stephane Zamia, Ph.D., and CEO of DSI. "The addition of this approach to Stago's portfolio will allow our customers to measure TG in real-time and in larger, scalable studies."
Operations and research at the company will remain independent within the Stago Group, and will report directly to the company's scientific and clinical department. The Stago Group believes that by remaining independently controlled, this start-up company will continue promising creativity leading to product development, citing their recent acquisition of BioCytex (Marseille, France), a company specializing in standardized kits for flow cytometric analysis of blood cells.
TG is a universal test capable of assessing a patient's global hemostatic balance in the instance of hemorrhage or thrombosis. Few methods before this had allowed for TG standardization and calibration. Thrombinoscope introduced a patented, sample-specific calibrator that allows for error correction due to inter-subject plasma composition and color variations, as well as substrate consumption. This method is both specific and sensitive, thereby giving increased relevance to this hemostatic test in academic research centers, pharmaceutical companies, and contract research organizations.
Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago, S.A.S. France (Asnières sur Seine, France), a developer and manufacturer of Hemostasis products.
Related Links:
Diagnostica Stago
Thrombinoscope
"The development potential of this new TG approach in hemostasis using the CAT system is very promising," noted Stephane Zamia, Ph.D., and CEO of DSI. "The addition of this approach to Stago's portfolio will allow our customers to measure TG in real-time and in larger, scalable studies."
Operations and research at the company will remain independent within the Stago Group, and will report directly to the company's scientific and clinical department. The Stago Group believes that by remaining independently controlled, this start-up company will continue promising creativity leading to product development, citing their recent acquisition of BioCytex (Marseille, France), a company specializing in standardized kits for flow cytometric analysis of blood cells.
TG is a universal test capable of assessing a patient's global hemostatic balance in the instance of hemorrhage or thrombosis. Few methods before this had allowed for TG standardization and calibration. Thrombinoscope introduced a patented, sample-specific calibrator that allows for error correction due to inter-subject plasma composition and color variations, as well as substrate consumption. This method is both specific and sensitive, thereby giving increased relevance to this hemostatic test in academic research centers, pharmaceutical companies, and contract research organizations.
Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago, S.A.S. France (Asnières sur Seine, France), a developer and manufacturer of Hemostasis products.
Related Links:
Diagnostica Stago
Thrombinoscope
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples